Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy in Phase 3 development for type 1 diabetes, for which Tolerx is partnered with GlaxoSmithKline. A second clinical product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for cancer. TRX1, a third immunotherapy candidate, is an anti-CD4 antibody that has been clinically evaluated for the treatment of aberrant or untoward immune responses.
The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and are being evaluated for potential benefit in the treatment of cancer and chronic viral infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.
Company Details
- Founded
- -
- Address
- 300 Technology Square,
- Phone
- (617)452-1300
- in****@****erx.com
- Industry
- Biotechnology
- Website
- tolerx.com
- Keywords
- biotechnology, cancer treatment, diabetes treatment, autoimmune disease, antibody treatment, immunotherapy.
- HQ
- Cambridge, MA
Tolerx, Inc. Questions
Tolerx, Inc.'s helpline number is (617)452-1300
Tolerx, Inc.'s website is tolerx.com
Tolerx, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tolerx-inc.
Tolerx, Inc.'s industry is
Biotechnology
Tolerx, Inc.'s top competitors are
Lodestar,
Michael Heath Construction Co,
Anokion,
Jonaire Inc,
C & A Cleaning Services Llc,
Mersana Therapeutics,
Six Therapeutics Inc.,
Empathy Home Health Care,
Affinity Business Development,
Alnylam Pharmaceuticals.
Tolerx, Inc.'s support email address is info@tolerx.com
Tolerx, Inc.'s categories are Biotechnology
Tolerx, Inc.'s founding year is 2000
